The Galapagos share

The Galapagos group CSR report
Galapagos NV • Annual Report 2018

Galapagos NV (ticker: GLPG) has been listed on Euronext Amsterdam and Brussels since 6 May 2005 and on the Nasdaq Global Select Market since 14 May 2015. Galapagos NV forms part of the Bel20 index (top 20 listed companies) on Euronext Brussels, the AEX Index (top 25 listed companies) on Euronext Amsterdam, and the Nasdaq Biotechnology Index on Nasdaq in New York.

The Galapagos share in 2018

In 2018, the average daily trading volume on Euronext was 440,551 shares and €38.7 million turnover. The daily trading volume on Nasdaq in 2018 was 113,218 ADSs and $11.7 million turnover.

Galapagos vs Next Biotech Index in 2018

Galapagos vs Nasdaq Biotechnology Index

Galapagos vs Nasdaq Biotechnology Index (line chart)

Investor relations activities

We attracted additional sell-side analyst coverage by U.S. and European banks in 2018. Our IR team presented at a number of conferences in 2018 and did several of broker-organized and self-organized roadshows throughout the U.S. and Europe. We presented 2017 Full Year, and Q1, Half Year, and Q3 2018 results, and our Annual R&D Update via webcasts.

The main topics of discussion with investors included the filgotinib development programs with collaboration partner Gilead, our Phase 3 plans with GLPG1690 in IPF patients, our ROCCELLA global Phase 2b trial with collaboration partner Servier in osteoarthritis, and our Toledo program for inflammation.